We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Aeras Global TB Vaccine Foundation of Bethesda, Maryland and Statens Serum
Institut (SSI) of Copenhagen, Denmark, announced a new collaboration on the
preclinical and clinical development of SSI's tuberculosis (TB) vaccine, HyVac4.
Sanofi pasteur, the vaccines business of the sanofi-aventis group, has received
a license from the Agence Francaise de Securite Sanitaire des Produits de Sante
(AFSSAPS) for a new polio vaccine, which is the first new vaccine developed
to fight that disease in decades.
Lexicon Genetics reached an agreement to settle its claim in Deltagen bankruptcy
proceedings and said its first-quarter revenue will exceed the high end of its
previous guidance as a result of the deal.
Serono and Syntonix Pharmaceuticals Inc. announced that they have entered into
an agreement under which Serono has licensed worldwide exclusive rights to Syntonix'
Transceptor and Synfusion technologies for the development and commercialization
of interferon-beta:Fc products. Syntonix' technologies may enable the development
of an interferon-beta therapy for multiple sclerosis (MS) that can be administered
by inhalation.
ICOS Corporation and privately held Caprion Pharmaceuticals Inc. announced that
they have entered into an agreement for the joint development of therapeutic
antibodies for the treatment of cancer.
A trio of final guidance documents focused on developing new ways to minimize
the safety risks of prescription drugs and biologics are not expected to lengthen
the product-approval process, a top FDA official said.
Coley Pharmaceutical has signed an exclusive global
license agreement with Pfizer that will allow the drug giant to develop, manufacture
and market Coley's experimental cancer treatment ProMune.